<DOC>
	<DOCNO>NCT02106520</DOCNO>
	<brief_summary>Hereditary Hemorrhagic Telangiectasia ( HHT ) rare ( ~ 1/6000 ) ubiquitous genetic disease . It associate abnormal angiogenesis autosomal dominant inheritance , lead telangiectasias arteriovenous fistula . More 95 % patient concerned epistaxis ( nosebleed ) . These event spontaneous , repeat , irregular , diurnal nocturnal , source anemia , disable socially embarrass . Anti-angiogenic treatment , include bevacizumab , new therapeutic option HHT . The aim study evaluate 3 month end treatment efficacy duration nosebleeds 3 different dos ( 25 , 50 75 mg ) bevacizumab administer nasal spray repeat manner ( 3 administration ) patient Hereditary Hemorrhagic Telangiectasia complicate nosebleed . This randomized , double-blind , placebo-controlled , seamless phase II/III study carry 4 group 20 patient first step 2 group 20 40 patient second step</brief_summary>
	<brief_title>Efficacy Bevacizumab Nasal Spray Treatment Epistaxis Hereditary Hemorrhagic Telangiectasia ( HHT )</brief_title>
	<detailed_description />
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Epistaxis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age ≥ 18 year . Patients give free inform signed consent . Patients affiliate social security scheme similar . Patients monitor clinically confirm HHT ( presence least 3 Curaçao criterion ) and/or confirm molecular biology . Patients undergone nasal surgery 3 month prior inclusion . Patient nosebleed monthly duration 20 minute justify followup grid complete least 3 month prior time inclusion . Women pregnant likely become course study . Patients affiliate social security scheme . Patients protect adult term law ( French Public Health Code ) . Refusal consent . Patients diagnosis HHT confirm clinically and/or molecular biology . Patients ongoing infectious condition . Participation another clinical trial within 28 day prior inclusion . Known hypersensitivity active ingredient one excipients . Known hypersensitivity product Chinese hamster ovary cell ( CHO ) human humanize recombinant antibody . Patients incompletely fill nosebleed grid 3 month precede treatment . Patients present nosebleed monthly average duration 3 month precede treatment 20 minute ( ( duration M1 + duration M2 + duration M3 ) / 3 ) . Remark : 3 month strictly precede treatment take account , even grid complete long period . Patients receive Avastin® intravenously 6 month prior inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Epistaxis</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>